孕期神经递质系统药物暴露与自闭症谱系障碍风险的关联
在完全校正模型中,34组药物中有5组与ASD风险存在名义显著关联,其中多数关联在调整母亲诊断数量后表现为风险降低,而神经元烟碱型乙酰胆碱受体α拮抗剂暴露与风险升高相关。
要点
- 多数影响神经递质系统的孕期药物暴露与ASD风险无显著关联。
- 调整母亲诊断数量后,大麻素受体激动剂等4组药物与ASD风险降低相关。
- 神经元烟碱型乙酰胆碱受体α拮抗剂暴露与ASD风险升高相关(HR 12.94)。
核心结论
- 在该样本中,大多数影响神经递质系统的药物与ASD风险估计无关联,需实验技术重复和/或验证。
研究设计与样本
- 病例对照研究,纳入1997年1月1日至2007年12月31日出生、随访至2015年1月26日的儿童,来自以色列单一健康维护组织。
- 识别出55组影响神经递质系统且在该样本中被孕妇处方的药物,比较产前暴露与未暴露儿童。
主要发现
- 在34组药物中,5组在完全校正模型中与ASD存在名义统计显著关联。
关键数值与推荐
- 使用Cox比例风险回归计算风险比(HR)及95% CI,校正相关混杂因素(如出生年份、母亲年龄、母亲精神与神经疾病史、母亲孕前1年全部医学诊断数量)。
临床怎么用
- 临床处方孕期药物时,应关注药物对神经递质系统的影响,但多数药物未显示与ASD风险显著关联。
- 对于神经元烟碱型乙酰胆碱受体α拮抗剂等显示风险升高的药物,需结合个体情况谨慎评估。
- 研究结果不能直接用于改变临床实践,需进一步验证。
局限性
- 研究为观察性设计,不能确定因果关系。
- 部分关联的置信区间较宽(如HR 12.94的95% CI 1.35-124.25),估计不精确。
- 需要实验技术进行重复和/或验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prenatal exposure to certain medications has been hypothesized to influence the risk of autism spectrum disorders (ASD). However, the underlying effects on the neurotransmitter systems have not been comprehensively assessed. OBJECTIVE: To investigate the association of early-life interference with different neurotransmitter systems by prenatal medication exposure on the risk of ASD in offspring. DESIGN, SETTING, AND PARTICIPANTS: This case-control study included children born from January 1, 1997, through December 31, 2007, and followed up for ASD until January 26, 2015, within a single Israeli health maintenance organization. Using publicly available data, 55 groups of medications affecting neurotransmitter systems and prescribed to pregnant women in this sample were identified. Children prenatally exposed to medications were compared with nonexposed children. Data were analyzed from March 1, 2017, through June 20, 2018. MAIN OUTCOME AND MEASURES: Hazard ratios (HRs) and 95% CIs of ASD risk associated with exposure to medication groups using Cox proportional hazards regression, adjusted for the relevant confounders (eg, birth year, maternal age, maternal history of psychiatric and neurologic disorders, or maternal number of all medical diagnoses 1 year before pregnancy). RESULTS: The analytic sample consisted of 96 249 individuals (1405 cases; 94 844 controls; mean [SD] age at the end of follow-up, 11.6 [3.1] years; 48.8% female), including 1405 with ASD and 94 844 controls. Of 34 groups of medications, 5 showed nominally statistically significant association with ASD in fully adjusted models. Evidence of confounding effects of the number of maternal diagnoses on the association between offspring exposure to medication and ASD was found. Adjusting for this factor, lower estimates of ASD risk among children exposed to cannabinoid receptor agonists (HR, 0.72; 95% CI, 0.55-0.95; P = .02), muscarinic receptor 2 agonists (HR, 0.49; 95% CI, 0.24-0.98; P = .04), opioid receptor κ and ε agonists (HR, 0.67; 95% CI, 0.45-0.99; P = .045), or α2C-adrenergic receptor agonists (HR, 0.43; 95% CI, 0.19-0.96; P = .04) were observed. Exposure to antagonists of neuronal nicotinic acetylcholine receptor α was associated with higher estimates of ASD risk (HR, 12.94; 95% CI, 1.35-124.25; P = .03). CONCLUSIONS AND RELEVANCE: Most of the medications affecting neurotransmitter systems in this sample had no association with the estimates of ASD risk. Replication and/or validation using experimental techniques are required.
引用
- Janecka M, Kodesh A, Levine SZ, et al. Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. JAMA Psychiatry. 2018. PMID: 30383108. doi:10.1001/jamapsychiatry.2018.2728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。